|Clone||13H4 / 4A4 / 34ßE12|
|Isotype||IgG / IgG2a / IgG1|
|Product Type||Primary Antibodies|
The combination of AMACR (P504S), p63, and HMW CK may be extremely useful for diagnosing PIN and small focus adenocarcinoma, especially in difficult cases and cases with limited tissues. The combination of p63 and HMW CK antibodies provides a save method for the detection of basal cells, while AMACR (P504S) labels only carcinoma cells and PIN lesions. P504S (AMACR, Alpha-methylacyl-CoA racemase) is an essential enzyme in the b-oxidation of branched-chain fatty acids. High expression of AMACR protein is found in prostate adenocarcinoma but not in benign prostate tissue by immunohistochemical staining in paraffin-embedded tissue. The expression of AMACR is also detected in prostate premalignant lesions, such as prostate intraepithelial neoplasia (PIN). The p63 protein, a homologue of the tumor-suppressor p53, is highly expressed in the nuclei of basal or progenitor layer of many epithelial tissues. p63 is detected in prostate basal cells in normal prostate glands and PIN. Other markers for basal cells are high molecular cytokeratins (CK 1, 5, 10 and 14), which can be labeled with HMW CK clone 34ßE12. In prostate adenocarcinoma basal cells disappear and staining with both p63 and HMW CK fails. Thus the combination of p63 and HMW CK is a useful tool as differential markers for benign prostate glands and adenocarcinoma (negative marker). 1. Human AMACR (P504S) protein, Alpha-Methylacyl CoA Racemase, 2. human p63 nuclear protein, and 3. high molecular weight cytokeratins (56-57 and 66-68 kDa).
Immunogen: 1. Human recombinant AMACR (P504S) protein, whole sequence (for rabbit monoclonal antibody 13H4); 2. Recombinant human p63 protein aa 1-205 (for mouse monoclonal antibody 4A4); 3. Cytokeratin extract of human stratum corneum (for mouse monoclonal antibody 34ßE12)
Affinity purified antibodies in PBS, BSA, sodium azide (0.09%)**. Use antibody dilution buffer (e.g. Art. No. PU002) containing sufficient protein and preservative.
Purification Method: Affinity purified antibodies in PBS, BSA, sodium azide (0.09%)**. Use antibody dilution buffer (e.g. Art. No. PU002) containing sufficient protein and preservative.
Species Reactivity: Human
Incubation Time: 60 min at RT
Working Concentration: (liquid conc.) 1:25-1:50
Pre-Treatment: Use formalin-fixed and paraffin-embedded sections; Retrieval conditions: Unmasking fluid T, TEC buffer (Tris/EDTA/Citrate) pH 8 (Art. No. DE005) in a pressure cooker at 100°C 20-40 minutes
Positive Control: Prostatic intraepithelial neoplasia
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
1. Jiang Z, Woda BA, Rock KL et al. (2001) P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 25:1397-1404. 2. Weinstein MH, Signoretti S, Loda M (2002) Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol. Dec;15(12):1302-8. 3. Luo J, Shan Zha, Wesley R, et al. (2002) Alpha methylacyl-CoA recemase, a new molecular marker for prostate cancer. Cancer Res 62:2220-2226. 4. Yang X.J., Lecksell K., Gaudin P., and Epstein J.I. (1999) Rare expression of high-molekular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. Am. J. Surg. Pathol. 23(2); 147-152.
Safety Datasheet(s) for this product:
/wp-content/uploads/SDS/Antibody SDS with Sodium Azide Noridic-MUbio.pdf